InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4C - quarterly 30 Oct 2015 3:32PM $0.115 $0.049 fallen by 57.39%
- Notice of Annual General Meeting/Proxy Form 12 Oct 2015 11:15AM $0.140 $0.049 fallen by 65%
- Prana reports FY15 financial results 27 Aug 2015 10:10AM $0.130 $0.049 fallen by 62.31%
- Form 20-F 27 Aug 2015 9:41AM $0.135 $0.049 fallen by 63.70%
- Appendix 4G 26 Aug 2015 5:39PM $0.135 $0.049 fallen by 63.70%
- Appendix 4E and Annual Report 2015 26 Aug 2015 5:29PM $0.135 $0.049 fallen by 63.70%
- Appendix 4C - quarterly 27 Jul 2015 2:17PM $0.160 $0.049 fallen by 69.38%
- Safety Outcomes of Alzheimer's IMAGINE Extension Trial 30 Jun 2015 6:38PM $0.150 $0.049 fallen by 67.33%
- Prana announces $6.8 million R&D refund 19 Jun 2015 10:27AM $0.170 $0.049 fallen by 71.18%
- Change of Director's Interest Notice - GK 1 Jun 2015 5:40PM $0.250 $0.049 fallen by 80.40%
- Approval of PBT2 Orphan Designation for Huntingtons Disease 1 Jun 2015 9:40AM $0.180 $0.049 fallen by 72.78%
- Appendix 3B and 708A notice 27 May 2015 5:09PM $0.165 $0.049 fallen by 70.30%
- Response to ASX Price Query 22 May 2015 8:38AM $0.190 $0.049 fallen by 74.21%
- EMA publishes Minutes Recommending Orphan Drug Status 22 May 2015 8:30AM $0.190 $0.049 fallen by 74.21%
- Appendix 4C - quarterly 28 Apr 2015 11:45AM $0.140 $0.049 fallen by 65%
- PBT2 recommended for orphan designation in Europe 28 Apr 2015 10:21AM $0.140 $0.049 fallen by 65%
- S&P DJ Indices Announces March Quarterly Review 6 Mar 2015 8:44AM $0.135 $0.049 fallen by 63.70%
- Appendix 4D Half Yearly Report and Accounts 24 Feb 2015 5:35PM n/a $0.049 n/a
- FDA End-of Phase 2 Status Update 13 Feb 2015 9:37AM $0.205 $0.049 fallen by 76.10%
- Appendix 4C - quarterly 30 Jan 2015 11:51AM $0.180 $0.049 fallen by 72.78%
- Response to ASX Price Query 12 Dec 2014 9:02AM $0.220 $0.049 fallen by 77.73%
- Appendix 4C - quarterly 30 Oct 2014 5:41PM $0.205 $0.049 fallen by 76.10%
- FDA Orphan Drug Designation for PBT2 for Huntington Disease 5 Sep 2014 1:33PM $0.330 $0.049 fallen by 85.15%
- Trading Halt 5 Sep 2014 10:21AM $0.330 $0.049 fallen by 85.15%
- Appendix 4E & Preliminary Final Report 29 Aug 2014 5:17PM $0.230 $0.049 fallen by 78.70%

126 - 150 of 331 results

Page 6 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.